SEC Form 4 · accession 0001209191-17-022582

Esperion Therapeutics, Inc. · ESPR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Daniel Janney

Director

Period of report

Mar 21, 2017

Accepted (ET)

Mar 23, 2017 · 4:45 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001434868

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Mar 21, 2017	S	121,340	$44.91	D	1,588,627	I	See Footnote
Common Stock^F3,F2	Mar 21, 2017	S	111,307	$45.43	D	1,477,320	I	See Footnote
Common Stock^F4,F2	Mar 21, 2017	S	59,798	$46.60	D	1,417,522	I	See Footnote
Common Stock^F5,F2	Mar 21, 2017	S	56,855	$47.54	D	1,360,667	I	See Footnote
Common Stock^F6,F2	Mar 21, 2017	S	700	$48.19	D	1,359,967	I	See Footnote
Common Stock^F7	holding	—	—		—	7,020	I	By Trust

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.12 - $45.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
F2The reportable securities are owned directly by Alta Partners VIII, L.P. ("APVIII"). The general partner of APVIII is Alta Partners Management VIII, LLC ("APMVIII"). Mr. Janney is a managing director of APMVIII, and he disclaims beneficial ownership of the shares held by APVIII, except to the extent of his pecuniary interest therein.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.125 - $46.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.125 - $47.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.
F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.125 - $48.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4.
F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.17 - $48.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4.
F7These shares are held by the Daniel Janney and Noelle Montgomery Family Trust DTD May 26, 1998 (the "Trust"). The Reporting Person is a Trustee of the Trust. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.